Clinical Trial News and Research

RSS

New clinical study focuses on investigational treatment to reduce impact of key protein from the brain

The Nantz National Alzheimer Center at Houston Methodist Hospital is part of a landmark clinical trial that looks at removing a key protein from the brain to prevent memory loss at least a decade before symptoms are noticed in healthy older adults.

12 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

QMUL, UCT researchers awarded £3.5m MRC grant to prevent TB in South African primary school children

The Medical Research Council has awarded a grant of £3.5m to researchers from Queen Mary University of London and University of Cape Town to carry out a trial to determine whether a weekly vitamin D supplement can prevent tuberculosis (TB) in South African primary school children.

12 Oct 2015

Discovery may help scientists to better predict how quickly HIV virus returns after patients stop treatment

Scientists are now better able to predict how quickly the HIV virus will return after individuals stop treatment following a discovery by researchers at UNSW Australia and the University of Oxford.

12 Oct 2015

Lilly acquires worldwide rights to intranasal glucagon from Locemia

Eli Lilly and Company and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia.

11 Oct 2015

Safety and immunogenicity clinical trial of Ebola vaccine regimen starts in Sierra Leone

Johnson & Johnson today announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies.

9 Oct 2015

FDA approves expanded indication for Optune device for brain cancer patients

The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.

9 Oct 2015

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

Today, the U.S. Food and Drug Administration approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in approximately 20 patients worldwide.

9 Oct 2015

Volunteer nurse back in isolation with Ebola complications

This morning Pauline Cafferkey, the nurse who survived infection with the Ebola virus, was airlifted to an isolation unit at the Royal Free Hospital in London after the Ebola virus was detected in blood samples.

9 Oct 2015

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.

9 Oct 2015

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF).

8 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

Boston Scientific closes additional financing with MValve Technologies

Boston Scientific Corporation today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS Valve, creating a unique mitral regurgitation (MR) treatment solution.

8 Oct 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

8 Oct 2015

Smoking cessation medication 46% effective in women

The most effective prescription drug used to quit smoking initially helps women more than men, according to a Yale School of Medicine study. The study, published Oct. 7 by the journal Nicotine and Tobacco Research, found that varenicline, marketed as Chantix, was more effective earlier in women, and equally effective in women and men after one year.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the efficacy and safety of TECFIDERA® (dimethyl fumarate) across a broad range of people with relapsing-remitting multiple sclerosis (RRMS).

7 Oct 2015

Clinical Trial News and Research

New clinical study focuses on investigational treatment to reduce impact of key protein from the brain

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

QMUL, UCT researchers awarded £3.5m MRC grant to prevent TB in South African primary school children

Discovery may help scientists to better predict how quickly HIV virus returns after patients stop treatment

Lilly acquires worldwide rights to intranasal glucagon from Locemia

Safety and immunogenicity clinical trial of Ebola vaccine regimen starts in Sierra Leone

FDA approves expanded indication for Optune device for brain cancer patients

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

Volunteer nurse back in isolation with Ebola complications

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

Boston Scientific closes additional financing with MValve Technologies

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Smoking cessation medication 46% effective in women

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer